Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note published on Tuesday morning. The brokerage issued a strong-buy rating on the stock.

Other equities analysts have also issued reports about the company. Truist Financial raised their price target on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, May 12th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $27.80.

Fresenius Medical Care Stock Performance

Shares of Fresenius Medical Care stock opened at $29.88 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The company has a market cap of $17.53 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The business has a 50 day moving average price of $25.22 and a 200-day moving average price of $23.84. Fresenius Medical Care has a 52 week low of $17.93 and a 52 week high of $30.29.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The company had revenue of $5.54 billion during the quarter, compared to the consensus estimate of $4.71 billion. Equities analysts anticipate that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 23rd will be given a dividend of $0.7871 per share. This represents a yield of 1.9%. This is a boost from Fresenius Medical Care’s previous annual dividend of $0.44. The ex-dividend date of this dividend is Friday, May 23rd. Fresenius Medical Care’s payout ratio is presently 49.11%.

Institutional Trading of Fresenius Medical Care

Hedge funds have recently made changes to their positions in the stock. Wayfinding Financial LLC purchased a new position in Fresenius Medical Care in the 1st quarter worth approximately $25,000. Spire Wealth Management purchased a new stake in Fresenius Medical Care during the 1st quarter valued at $27,000. Smartleaf Asset Management LLC raised its stake in Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares during the last quarter. Brooklyn Investment Group raised its stake in Fresenius Medical Care by 424.5% during the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock valued at $32,000 after buying an additional 1,040 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Fresenius Medical Care by 234.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company’s stock valued at $71,000 after buying an additional 2,208 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.